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Increased Plasmodium chabaudi malaria 
mortality in mice with nutritional iron deficiency 
can be reduced by short-term adjunctive iron 
supplementation
Filip C. Castberg1,3 , Lasse Maretty1, Trine Staalsoe1, Casper Hempel1,5, Erik Clasen‑Linde4, Lars Hviid2,3 
and Jørgen A. L. Kurtzhals1,3*
Abstract 
Background: Iron deficiency is the most widespread nutrient deficiency and an important cause of developmental 
impairment in children. However, some studies have indicated that iron deficiency can also protect against malaria, 
which is a leading cause of childhood morbidity and mortality in large parts of the world. This has rendered interven‑
tions against iron deficiency in malaria‑endemic areas controversial.
Methods: The effect of nutritional iron deficiency on the clinical outcome of Plasmodium chabaudi AS infection in 
A/J mice and the impact of intravenous iron supplementation with ferric carboxymaltose were studied before and 
after parasite infection. Plasma levels of the iron status markers hepcidin and fibroblast growth factor 23 were meas‑
ured in animals surviving and succumbing to malaria, and accompanying tissue pathology in the liver and the spleen 
was assessed.
Results: Nutritional iron deficiency was associated with increased mortality from P. chabaudi malaria. This increased 
mortality could be partially offset by carefully timed, short‑duration adjunctive iron supplementation. Moribund ani‑
mals were characterized by low levels of hepcidin and high levels of fibroblast growth factor 23. All infected mice had 
extramedullary splenic haematopoiesis, and iron‑supplemented mice had visually detectable intracellular iron stores.
Conclusions: Blood transfusions are the only currently available means to correct severe anaemia in children with 
malaria. The potential of carefully timed, short‑duration adjunctive iron supplementation as a safe alternative should 
be considered.
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Background
Iron deficiency is the most widespread nutrient defi-
ciency, causing considerable developmental impairment 
in children [1–4], and it is a major cause of anaemia in 
tropical and low-income countries [5, 6]. However, iron 
deficiency has also been proposed to protect against 
malaria [7–10], and there is some evidence that iron 
supplementation can increase malaria susceptibility 
[11, 12]. This has made the concept of dietary iron sup-
plementation in areas of stable transmission of malaria 
parasites somewhat controversial. The issue is com-
plicated by the inherent difficulty in accurately assess-
ing iron status in malaria patients, because all known 
markers of iron stores are increased by inflammation or 
are otherwise affected by malaria [13]. This means that 
severely ill malaria patients might inadvertently be mis-
classified as iron replete. Concurrent helminth infections, 
haemoglobinopathies, glucose-6-phosphate-dehydroge-
nase, and molecular haptoglobin variants can all affect 
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measurements, adding further complexity to epidemio-
logical studies in malaria-endemic areas [14].
To some extent, these difficulties can be overcome in 
studies of experimental animal models of malaria, as 
these allow full control over the cause, degree, and allevi-
ation of iron deficiency, as well as control over the timing 
and clinical consequences of malaria infection in iron-
deficient and iron-replete animals. Nevertheless, such 
studies have also shown conflicting results [15–19].
In the present study, the effect of nutritional iron defi-
ciency and iron supplementation on survival and infec-
tion parameters in a murine model of malaria is explored. 
The focus is on ferric carboxymaltose, which is an effec-
tive parenteral iron supplementation that can be admin-
istered easily and safely [20–24]. This supplement offers 
a cost-effective and fast correction of iron deficiency that 
overcomes the defective absorption of oral iron among 
parasitaemic recipients, and is without the adverse effects 
of earlier intravenous preparations.
Methods
Experimental animal model
Pathogen-free male A/J mice were purchased from Har-
land Laboratories (Venray, Netherlands) or Jackson Labo-
ratories (Sacramento, CA, USA). The animals were kept 
under standard conditions in a closed, ventilated rack sys-
tem with food/water access ad  libitum. Control animals 
were fed a standard, iron-replete diet (100 mg Fe/kg, Altro-
min 1319), whereas test animals were fed an iron-deficient 
diet (5  mg Fe/kg; Altromin C1038, Lage, Germany) to 
induce iron deficiency anaemia. Haemoglobin levels were 
monitored weekly until levels were 20% below those in 
control animals. This was usually achieved in 3–4 weeks.
Some animals were treated daily for 3 consecutive days 
with i.v. injection (200 μL) of either ferric carboxymaltose 
(equivalent of 600 μg Fe; Ferinject, Vifor Pharma, Glatt-
brugg, Switzerland) [25] or ferrous sulfate p.o. (600 μg Fe 
in 200 μL water). In those experiments, control animals 
received the same volume of either carboxymaltose i.v. 
(900 μg) or saline p.o.
For malaria infection, P. chabaudi AS-infected erythro-
cytes (IEs), obtained from frozen stock (originally a gift 
from David Walliker, University of Edinburgh, UK), were 
used. After thawing, the parasites were passaged in donor 
mice before infecting study animals i.p. [26].
A body temperature below 30 °C was used as a humane 
endpoint for death, and such severely hypothermic ani-
mals were killed by cervical dislocation as required by the 
Inspectorate [27].
Outcome measurements
Weight, body temperature, haemoglobin level, reticulo-
cytaemia, and asexual parasitaemia were measured daily 
until malaria symptoms developed. Subsequently, the 
body temperature and clinical condition of the animals 
were checked thrice daily.
Body temperatures were measured with an infrared 
thermometer (845, Testo, Lenzkirch, Germany), with 
temperatures below 31  °C further assessed by a rectal 
probe (DM852, Ellab, Hillerød, Denmark), as described 
[27]. Haemoglobin levels were measured in blood 
from tail nicks by alkaline haematin D–575 spectro-
photometry, as described [28]. Reticulocytaemias and 
asexual parasitaemias were determined by flow cytom-
etry and assessment of DNA/RNA content of acrid-
ine orange-labelled blood as described   [21, 29]. FGF23 
was measured using a C-terminal, homologous two-site 
enzyme-linked immunosorbent assay (ELISA), catalogue 
number #60-6300 (Immutopics Inc, CA, USA). Hepcidin 
(hepc-1) was detected with a solid-phase ELISA, based 
on the principles of competitive binding, catalogue num-
ber SKU# HMC-001, Intrinsic Lifesciences, CA, USA.
Histochemistry
In some experiments, mice were censored to allow har-
vesting of organs at different time points during infec-
tion. These animals were anesthetized using fentanyl/
fluanisone (Hypnorm) and Midazolam i.p., immediately 
perfused with saline and subsequently perfusion fixated 
using formaldehyde 4%, pH 7.4, and killed in the process. 
Livers and spleens were initially incubated in formalde-
hyde (24  h) and then stored in 70% ethanol. All organs 
were embedded in paraffin, sectioned (2 µm), and stained 
using Haematoxylin–Eosin and Perls’ Prussian Blue iron 
staining. Sections were evaluated by light microscopy. 
The examiner was blinded to treatment group affiliations.
Statistics
Statistical analyses were done in SAS v. 9.4 (SAS Insti-
tute, NC, USA). The log-rank test was used to assess the 
statistical significance of survival effects, and continuous 
outcome measures were analysed using a mixed-effects 
model (Autoregressive, order 1) with individual mice and 
treatment groups included as repeated and fixed effects, 
respectively. Hepcidin and FGF23 levels were analysed 
using log-transformed values in Satterthwaite’s approxi-
mate t test and ANOVA. P values < 0.05 were considered 
statistically significant.
Results
Determination of appropriate inoculum size
To establish an appropriate inoculum size that would 
result in mortality in some but not all infected control 
animals, groups of mice i.p. were inoculated with increas-
ing numbers of IEs (1 ×  104 −  5 ×  106) (Fig.  1). In all 
groups receiving > 1 × 104 IEs, some or all the mice died 
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or had to be killed (due to legal requirements, see Meth-
ods) before the end of the experiment (Fig. 1a). The body 
temperature of surviving animals decreased from Day 5 
to Day 8–9 post-inoculation, followed by gradual recov-
ery, until temperatures had returned to normal about 
Day  12 (Fig.  1b). Parasitaemias increased until Day  7 
b
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Fig. 1 Establishment of inoculum size. Clinical course in mice (5 per group) infected intraperitoneally with P. chabaudi AS‑IEs on Day 0 [1 × 104 
(black circle red line), 5 × 104 (black square blue line), 1 × 105 (black diamond purple line), 5 × 105 (black times green line), 1 × 106 (black triangle 
grey line), 5 × 106 (black inverse triangle black line)]. Panels depict a survival, b temperature, c parasitaemia, d weight change, e haemoglobin, and 
f reticulocyte fraction. Group means (symbols) and SD (error bars; b–f) are indicated
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post-infection, followed by a decline to very low levels by 
Day 10 (Fig. 1c). Changes in weight (Fig. 1d), haemoglo-
bin concentration (Fig. 1e), and reticulocytaemia (Fig. 1f ) 
were essentially independent of inoculum size (Fig.  1d). 
Based on these data, inocula of 1 ×  104 or 1 ×  105 IEs 
were used in all subsequent experiments.
Carboxymaltose treatment reduces malaria mortality 
in iron‑replete animals
To assess if the planned iron supplementation regimen 
would by itself affect the course of malaria even in iron-
replete animals, P. chabaudi AS-infected (1  ×  105 IEs 
i.p.) mice were treated once daily from Day  7 to Day  9 
post-infection with saline, carboxymaltose, or ferric car-
boxymaltose (Fig. 2). Mortality was lower in the groups 
treated with ferric carboxymaltose (mortality 19%; 
P = 0.07) or carboxymaltose (13%; P = 0.03), compared 
to the saline-treated group (mortality 50%) (Fig.  2a). In 
contrast, body temperatures (Fig.  2b), parasitaemias 
(Fig. 2c), weights (Fig. 2d), haemoglobin levels (Fig. 2e), 
and reticulocytaemias (Fig.  2f ) were essentially identi-
cal among all three groups. As mortality was similar in 
the ferric carboxymaltose- and carboxymaltose-treated 
groups (P = 0.7), these results indicate that the effect on 
mortality mediated by the carbohydrate and/or its degra-
dation products was not affected by its Fe-complex. The 
reduced mortality could reflect reduced hypoglycaemia 
in both the ferric carboxymaltose- and carboxymaltose-
treated groups [30, 31]. Therefore, carboxymaltose-
treated animals were used as controls in the experiments 
where the effect of ferric carboxymaltose was tested in 
iron-deficient animals.
Nutritional iron deficiency aggravates the course 
of malaria
To study the effect of nutritional anaemia on the clinical 
course of P. chabaudi AS infection, iron-replete and iron-
deficient animals were infected (1 × 104 IEs i.p.), and the 
course of infection was observed (Fig. 3). Although this 
inoculum was established as non-lethal in iron-replete 
animals (Fig.  1a), all the infected iron-deficient animals 
in this experiment died or had to be killed (Fig. 3a). All 
uninfected animals survived, whether iron-deficient 
or iron-replete. In the infected animals, temperatures 
dropped slightly (iron-replete animals) or precipitously 
(iron-deficient animals) from around Day  6 (Fig.  3b), 
although parasitaemias (Fig.  3c) and weights (Fig.  3d) 
developed similarly in iron-deficient and -replete 
infected mice (Fig. 3c). Interestingly, infected iron-replete 
and iron-deficient animals became similarly and severely 
anaemic (Fig.  3e), despite their very different haemo-
globin levels at the outset of the experiment (Fig.  3e). 
Substantial reticulocytaemia was observed in infected 
animals (Fig.  3f ). In conclusion, nutritional iron defi-
ciency made the mice more susceptible to P. chabaudi AS 
infection and led to a fatal outcome of a normally non-
lethal infection. Iron supplementation had no effect on 
parasitaemia, which was similar in all groups (Fig.  3c). 
This study is a refinement from two pilot experiments 
with similar results using iron-deficient infected saline 
controls.
The protective effect of iron supplementation critically 
depends on when it is given
Next, it was tested whether iron supplementation could 
ameliorate the observed aggravated course of P. chabaudi 
AS infection in iron-deficient mice (Fig. 4). To that end, 
the course of infection in groups of iron-deficient animals 
was compared following inoculation as above (1  ×  104 
IEs i.p.). The following regimens of iron supplementation 
were tested: (i) ferric carboxymaltose i.v. from 4 to 2 days 
before parasite inoculation, (ii) ferric carboxymaltose i.v. 
from 7 to 9 days after inoculation, and (iii) ferrous sulfate 
p.o. from 7 to 9 days after inoculation. Iron-replete and 
iron-deficient animals receiving carboxymaltose i.v. from 
7 to 9 days after inoculation were included as controls.
Mortality was observed in all groups except the iron-
replete control group (Fig. 4a). Mortality among the iron-
deficient control animals was substantial (62%) but lower 
than the uniform mortality seen in the previous experi-
ment, probably due to the protective effect of carboxy-
maltose used here. Iron supplementation on Day  7 to 
Day  9 post-inoculation reduced mortality, whether sup-
plementation was given as ferric carboxymaltose (20% 
mortality; P = 0.05) or as ferrous sulfate (31% mortality; 
P = 0.26). However, in striking contrast, ferric carboxy-
maltose given to iron-deficient animals a few days prior 
to parasite inoculation had no protective effect (mortality 
62%, P = 0.64), and in fact seemed to cause a more rapid 
onset of fatal pathology compared to the control mice.
Body temperatures (Fig.  4b), parasitaemias (Fig.  4c), 
and reticulocytaemias (Fig.  4f ) developed similarly in 
all groups of iron-deficient mice regardless of the sup-
plementation regimens. With respect to weights, mice in 
all groups lost weight in a similar way until about Day 11 
(Fig.  4d). However, the normal recovery of body weight 
following the parasitaemic crisis seen in the iron-replete, 
carboxymaltose-treated control mice was completely 
absent from the iron-deficient control mice treated the 
same way. Iron-supplementation of iron-deficient mice 
allowed the mice to regain some of the malaria-induced 
weight loss, in particular when treatment was given 
before the parasite infection (Fig.  4d). Ferric carboxy-
maltose appeared more efficient than ferrous sulfate in 
that respect. Haemoglobin levels (Fig.  4e) were initially 
higher among the iron-deficient mice that received ferric 
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carboxymaltose prior to inoculation compared to the 
other iron-deficient mice, and were similar to those of 
iron-replete animals from Day  6 onwards. In all study 
groups, haemoglobin levels fell from about Day  5 to 
about Day  11, followed by recovery in the iron-replete 
controls and the iron-supplemented, iron-deficient mice. 
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Fig. 2 Effect of ferric carboxymaltose on Plasmodium chabaudi infection. Clinical course in mice infected intraperitoneally with 1 × 105 P. chabaudi 
AS‑IEs on Day 0, and treated with daily (Days 7–9 post‑inoculation only) i.p. injection of saline (black circle red line), carboxymaltose (black square 
blue line), or ferric carboxymaltose (black diamond purple line). Panels depict a survival, b temperature, c parasitaemia, d weight change, e haemo‑
globin, and f reticulocyte fraction. Initial group sizes, group means (symbols) and SD (error bars; b–f) are indicated
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Fig. 3 Effect of nutritional anaemia on Plasmodium chabaudi infection. Clinical course in uninfected (white circle red line, black circle purple line) 
and P. chabaudi AS‑infected (1 × 104 IEs i.p., white square blue line, black square green line), iron‑deficient (white circle red line, white square blue 
line) or iron‑replete mice (black circle purple line, black square green line). Panels depict a survival, b temperature, c parasitaemia, d weight change, 
e haemoglobin, and f reticulocyte fraction. Initial group sizes, group means (symbols) and SD (error bars; b–f) are indicated. For clarity, data regard‑
ing non‑infected control animals (100% survival) are not shown in a
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Fig. 4 Effect of iron supplementation on Plasmodium chabaudi infection. Clinical course in P. chabaudi AS‑infected (1 × 104 IEs i.p.), iron‑replete 
(black circle red line) or iron‑deficient mice (white circle blue line, white diamond purple line, white triangle green line, white square grey line), 
treated on Day  −4 to Day −2 before infection only (white diamond purple line) or on Day 7 to Day 9 post‑infection only (black circle red line, white 
circle blue line, white diamond purple line, white triangle green line) with carboxymaltose i.p. (black circle red line, white circle blue line), ferric 
carboxymaltose i.p. (white diamond purple line, white triangle green line), or ferrous sulfate p.o. (white square grey line). Panels depict a survival, b 
temperature, c parasitaemia, d weight change, e haemoglobin, and f reticulocyte fraction. Initial group sizes, group means (symbols) and SD (error 
bars; b–f) are indicated
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This was most pronounced among mice receiving ferric 
carboxymaltose, in which recovery was similarly to that 
in the replete animals. No recovery in haemoglobin lev-
els was seen among the non-supplemented iron-deficient 
animals.
In conclusion, iron supplementation can alleviate 
malaria-related mortality in iron-deficient mice, but the 
protective effect depends critically on the timing of the 
supplementation. This study is a refinement from a pilot 
experiment with similar results using iron-deficient 
infected saline controls.
Serological iron status markers and haematopoietic 
histopathology in malaria‑infected mice
Hepcidin is a peptide hormone that negatively regu-
lates dietary iron absorption. Hepcidin levels increase in 
response to inflammation, but are decreased in anaemia 
[32, 33]. The hormone has anti-inflammatory proper-
ties in mice [34]. Fibroblast growth factor 23 (FGF23) 
is a bone-regulating hormone that has been reported 
to correlate with iron status irrespective of inflamma-
tory status, although the evidence is equivocal [35, 
36]. To assess the utility of these markers in the model, 
their levels were measured in plasma samples obtained 
at different time points from the animals used in the 
experiments reported above (Fig.  5). Hepcidin levels 
in uninfected mice fell in two clear groups depending 
on iron status (Fig.  5a, P =  0.009). Contrary to expec-
tations, only four of ten uninfected, iron-deficient mice 
had elevated FGF23, however, a significant difference 
was still detected between iron-deficient and iron-
replete controls (Fig.  5a, P  =  0.009). Hepcidin levels 
were clearly driven by anaemia and tended to be lower 
in infected than uninfected iron-replete mice (Fig.  5a, 
P = 0.07). A trend towards high FGF23 and low hepcidin 
in all fatal cases was noticed (Fig.  5, large symbols). In 
order to substantiate this and to study the effect of treat-
ment regimens on hepcidin and FGF23, an experiment 
with infected mice only was conducted. Ferric carboxy-
maltose-treated mice had significantly higher hepcidin 
levels than the other groups (Fig.  5b, P  =  0.0001). As 
in the former experiment (Fig.  5a), iron-depleted mice 
showed a dichotomy in FGF23 levels, and all fatal cases 
had high FGF23 (Fig. 5b). Across the iron deficient mice, 
fatal cases had significantly higher FGF23 than non-fatal 
cases (P = 0.0001).
Also, the livers and spleens of surviving animals at the 
end of the experiments (Day  22) were examined, when 
remaining mice were killed. All mice showed evidence 
of extramedullary haematopoiesis in the spleen. Iron-
replete mice and ferric carboxymaltose-supplemented 
iron-deficient mice had intracellular iron stores in the 
spleen (Fig. 6), whereas this was not seen in carboxymalt-
ose- or ferrous sulfate-treated mice except in one carbox-
ymaltose-treated mouse with scarce iron stores. Minor 
areas of microsteatosis and necrosis were observed in 
livers, most prominently in animals that died of malaria, 
but the severity of these changes was not sufficient to 
be considered the cause of death, and no attempts were 
made to quantify the lesions.
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Discussion
Iron is an essential nutrient, but its redox properties 
makes it potentially cytotoxic. Levels of non-transferrin-
bound iron ions are therefore tightly regulated by hor-
mones such as hepcidin. In the face of infection, a balance 
must furthermore be struck between the host need for 
iron and the potential benefits of minimizing the availabil-
ity of this nutrient to invading microorganisms [37]. This 
has created substantial controversy regarding the role of 
iron status in host health versus susceptibility to impor-
tant infectious diseases such as malaria, and the relative 
benefits and detriments of correcting iron deficiency by 
dietary supplementation in malaria-endemic areas [38].
In the present study, nutritional iron deficiency was 
found to seriously aggravate P. chabaudi AS infection in 
A/J mice. Thus, an inoculum size that normally produced 
a self-limiting infection in iron-replete animals caused 
substantial mortality among iron-deficient mice. The 
obligation to kill animals with a body temperature below 
30 °C (to minimize suffering) may have led to some over-
estimation of mortality, but these animals were all clini-
cally assessed moribund, why the implementation of this 
humane endpoint did not markedly affect the outcome of 
the experiments or the conclusions that can be drawn. As 
such, the presented data are at variance with experimen-
tal animal studies [15, 18] and human field studies that 
have indicated that iron deficiency can protect against 
malaria [7, 9, 10, 39].
Both altered iron bioavailability and erythrocyte physi-
ology have been implicated as mechanisms underlying 
the putative protective effect of iron deficiency [19, 40]. 
Clark et al. speculated that iron deficiency might induce 
a reduction in the erythropoietic rate and the synthesis of 
microcytic, iron-deficient erythrocytes unsuitable as host 
cells for the parasites [41]. In contrast, Matsuzaki-Moriya 
et al. found that iron deficiency anaemia did not in itself 
have an effect on parasite growth, and instead suggested 
that parasitized erythrocytes from malaria patients with 
iron deficiency anaemia are more susceptible to phago-
cytosis than control cells  [18]. However, there have also 
been studies challenging the protective effect of iron 
deficiency. Thus, Lelliott et  al. found that mice carrying 
a missense mutation in the transferrin receptor 1 gene, 
which renders them anemic, showed higher P. chabaudi 
parasitaemias and mortality than wildtype mice [19], 
similar to the findings in the present study. Furthermore, 
iron is required for normal immune function, and iron 
deficiency anaemia is a risk factor in acute lower respira-
tory tract infection and in acute otitis media [42, 43].
With respect to the malaria consequences of correcting 
iron deficiency, this study documents a markedly benefi-
cial effect of short-term iron supplementation on the sur-
vival of iron-deficient, P. chabaudi AS-infected A/J mice. 
The iron supplementation did not lead to increased para-
sitaemia, in agreement with our previous safety study 
[21]. On the other hand, it also did not reduce parasi-
taemia, thus suggesting that the improved survival rates 
were not due to a direct effect on parasites but rather 
due to an improved host response. In the initial survival 
experiment, using a lethal inoculum (Fig. 2), the effect on 
survival might be ascribed to reversal of hypoglycaemia 
[30, 31], since additional experiments showed a similar 
survival effect after administration of dextrose (unpub-
lished data). However, in iron-deficient mice infected 
with low inoculum, the survival mediated by ferric car-
boxymaltose was not due to a glycemic effect, since car-
boxymaltose did not rescue the mice. Further studies are 
needed to dissect the host effects causing vulnerability 
to P. chabaudi in iron deficient mice, and how these are 
affected by ferric carboxymaltose.
This study’s results also indicate that the temporal rela-
tionship between iron deficiency and parasitaemia is 
important. Thus, restoration of iron stores immediately 
prior to infection did not improve survival in our hands, 
but rather tended to hasten fatal outcomes. These find-
ings are in line with those of Clark et al., which led them to 
Fig. 6 Intracellular iron stores in the spleen. Perl’s Prussian Blue iron 
stain of the spleen from an iron deficient mouse that received intrave‑
nous ferric carboxymaltose. Iron deposits within macrophages appear 
bright blue. Five spleens of surviving animals randomly selected from 
every group (n = 25) were examined at the end of the experiment 
(Day 22), when the mice were killed. All iron‑replete mice and ferric 
carboxymaltose‑supplemented iron‑deficient mice had intracellular 
iron stores in the spleen, whereas this was not seen in any of the 
carboxymaltose‑ or ferrous sulfate‑treated mice (not shown) except 
scarce amounts of iron in 1 of 5 iron‑deficient mice that received 
carboxymaltose Day 7 to Day 9 post‑infection
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suggest a period of vulnerability during the transition from 
iron deficiency to iron replete status [41]. Thus, a ‘win-
dow of opportunity’ may exist, where adjunct intravenous 
iron supplementation would be beneficial. In that context, 
it may be worth noting that Chang et al. found that early 
reticulocytosis increased morbidity in a murine malaria 
model, whereas late reticulocytosis had the opposite effect 
[44]. Furthermore, the study’s findings suggest that iron 
supplementation should be administered over as short 
a period as possible in order to reduce the period of vul-
nerability, and preferably while taking precautions against 
malaria and other infections. In this connection, it should 
be noticed that the protective effect of the long-acting 
partner drug (e.g. lumefantrine or piperaquine) may shield 
against a temporary risk of malaria if i.v. iron is adminis-
tered concomitantly with artemisinin-based combination 
therapy.
The fact that this study was based on pilot experiments, 
and thus had clearly predefined hypotheses, supports 
the conclusions regarding an effect of iron deficiency as 
well as of ferric carboxymaltose therapy on severity of P. 
chabaudi infections. However, the data should be inter-
preted with caution.
Previous clinical studies of iron supplementation have 
shown conflicting results. While some findings sug-
gest that supplementation may be unwise [12, 45], oth-
ers reported no negative effect on malaria susceptibility 
of iron supplementation [46–48]. Recent meta-analyses 
indicate that iron supplementation does not increase the 
risk of malaria or malaria-related death, when regular 
surveillance and treatment services are provided [49, 50].
This study’s results do not support the proposition by 
Braithwaite et al. that FGF23 can be used as a marker of 
iron status in patients exposed to malaria [35], which 
would be an improvement over hepcidin, which is both 
affected by and itself affecting inflammation [32, 34]. In 
particular, mice with nutritional iron deficiency could have 
either high or low FGF-23, indicating that this is not a use-
ful marker of iron deficiency during malaria. Furthermore, 
all dying mice had severe anaemia, low hepcidin levels and 
high FGF23 levels. The data do not allow a conclusion on 
whether the high FGF23 levels in these mice were primar-
ily caused by anaemia or inflammation [36]. The combina-
tion of high FGF23 and low hepcidin levels could possibly 
serve as a marker of severity of malaria and a predictor for 
outcome. Further research on how iron-regulating hor-
mones affect survival in complicated malaria is warranted.
Conclusion
This study provides evidence that nutritional iron defi-
ciency is a risk factor in malaria and suggests that the 
risk can be alleviated by carefully timed, short-dura-
tion adjunct iron supplementation. Intravenous iron 
treatment in low-resource settings may not be easily 
implemented, but considering that the only currently 
available adjunctive treatment for severe malarial anae-
mia is blood transfusion, with its accompanying risks of 
infection and anaphylactic reactions, it may nevertheless 
be the better and safer alternative.
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